Biocracked
Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
Research

Injeksi Lipolisis CBL-514: Peta Bukti Fase II

Dr. Synapse · · 6 min read

Injeksi Lipolisis CBL-514: Peta Bukti Fase II

CBL-514 iku suntikan molekul cilik sing saiki lagi diteliti supaya sel lemak (adiposit) ngalami apoptosis lan nyuda kantong lemak ing weteng sing diobati. Uji fase II sing siji‑blind lan kontrol plasebo, kang diterbitake ing Aesthetic Surgery Journal taun 2025, ngacak 76 peserta lan nglaporake penurunan volume lemak sing diukur nganggo ultrasound luwih signifikan tinimbang saline, nanging bobot awak ora owah sacara statistik. Asil iki menarik, nanging desainé nduwèni watesan nyata. Tulisan iki nyorot apa sing dibuktekaké uji coba, apa sing ora bisa dibuktekaké, lan ing ngendi panggonan panliten iki kudu dilanjutaké.

Cathetan: Artikel iki ora menehi saran medis. CBL‑514 isih ing tahap investigasi lan mung diwènèhi marang peneliti uji coba, ora kanggo dipigunakaké déwé.

Apa iku CBL‑514 (lan apa dudu)

Jeneng resmi yaiku CBL‑514; kadang‑kadang kacat ing artikel dadi CL‑514. Senyawa iki asalé saka Caliway Biopharmaceuticals (New Taipei City, Taiwan). Ing studi iki, CBL‑514 disuntikaké subkutan ing wilayah sing diobati, yaiku perut. Dudu suplemen, dudu pil oral, lan dudu produk konsumen sing wis disetujoni. Saiki durung ana persetujuan saka FDA. Siji‑sijiné suntikan sing wis disetujoni FDA kanggo ngurangi lemak yaiku ATX‑101 (asam deoksikolik, Kybella), lan mung kanggo lemak submental (ngisor dagu).

Artikel iki ora nerbitaké struktur kimia CBL‑514, mula ora ana dhaptar bahan sing bisa dianalisis.

Sumber utama yaiku:

Gold M, Schlessinger J, Goodman GJ, Dayan S, DuBois J, Ling YF, Sheu AY, Ho WWS, Chou YC. Aesthetic Surgery Journal. 2025;45(6):611‑620. doi:10.1093/asj/sjaf032; ClinicalTrials.gov NCT04897412.

Artikel iki dapat diakses bebas: https://pmc.ncbi.nlm.nih.gov/articles/PMC12080885/.

Mekanisme sing diusulake: laporan perusahaan, non‑klinis

Makalah fase IIa sadurunge (Goodman et al., 2022) luwih cilik lan open‑label, tanpa grup plasebo. Ing laporan non‑klinis kasebut, CBL‑514 diduga ngendhegake kinase sel‑hidup DYRK1b, nambahake mediator apoptosis caspase‑3 lan Bax/Bcl‑2, lan nyebabake apoptosis adiposit kanthi dosis‑dependen, baik ing in‑vitro maupun in‑vivo. Klaim mekanisme iki diparingi referensi menyang laporan rahasia Caliway sing durung dipublikasikaké.

Mekanik iki saéngga isiné hipotesa adhedhasar asil non‑klinis sponsor. Ora ditemokaké bukti sing padha ing manungsa ing uji iki. Mekanisme iki nerangake patine sel lemak lokal, dudu peningkatan metabolisme umum, dudu "obong kalori", lan dudu penurunan bobot awak sakabèhé. Frasa "obong lemak" sing asring dipigunakaké para bio‑hacker ora cocog kanggo konteks iki.

Kepiye uji fase II iki dibangun

  • Desain: acak, siji‑blind, paralel, kontrol plasebo, dilakokaké Februari 2022 nganti Maret 2023 ing lima pusat ing AS lan Australia.
  • Randomisasi: rasio 2 : 1 (CBL‑514 : plasebo saline).
  • Blinding: mung peserta sing diwènèhi blinding visual. Peneliti, staf situs, lan sponsor (kalebu medical monitor) ora diblind. Dadi iki dudu uji double‑blind.
  • Peran sponsor: Caliway melu ing desain, pangumpulan data, analisis lan interpretasi, nulis manuskrip, lan mutusaké ngirim asil.
  • Kelayakan: umur 18‑64 tahun, BMI > 18,5 lan < 35, bobot paling ora 50 kg, ketebalan kulit perut 3‑8 cm, lan fungsi hati, ginjel, kardiovaskular, lan imunitas normal.
  • Aturan stabilitas bobot: owah‑owahan bobot ≥ 3 kg saka baseline bakal njalari penghentian partisipasi.

Dosis lan jadwal sing dipigunakaké

Dosisé 2 mg/cm², maksimal 600 mg saben perawatan. Saben perawatan mbutuhake 25‑50 suntikan, adhedhasar kebijaksanaan peneliti, kanthi jarak antar‑suntikan 2,45 cm. Saben suntikan ngirim 2,4 mL CBL‑514 utawa volume sing padha saka saline. Peserta bisa nampa maksimum 4 perawatan, saben‑semené 4 minggu, banjur dipantau maneh 4 lan 8 minggu sawise perawatan pungkasan. Iki mung protokol uji klinis, dudu regimen sing diwènèhi konsumen.

Cara ngukur lemak

Lemak diukur nganggo ultrasound ing papat titik (kanan 4 cm, kanan 10 cm, kiwa 4 cm, kiwa 10 cm saka titik referensi abdomen). Saben titik diwènèhi telung scan, banjur rata‑rata. Sonografer terlatih ngitung volume kanthi rumus kuboid: area perawatan = 300 cm² × rata‑rata ketebalan lemak. Fotografi 3D uga dipigunakaké kanggo verifikasi visual. Titik akhir utama yaiku persentase peserta sing ngalami pengurangan ≥ 150 mL ing follow‑up 4 lan 8 minggu.

Sapa sing sejatine ana ing data

Saka 130 calon peserta, 81 mlebu lan 76 diacak (50 ing grup CBL‑514, 26 ing grup plasebo). 75 peserta tetep nampa perawatan (49 CBL‑514, 26 plasebo). 38 rampung studi kanthi lengkap, 37 ora rampung, ngasilaké tingkat attrisi 49,3 %. Alasan non‑completion antarane kelangan follow‑up (6), mundur sukarela (7), instabilitas bobot (7), ora bisa njaga jadwal (6), lan adverse event (4).

Populasi intention‑to‑treat (ITT) kalebu 76 peserta; populasi per‑protocol (PP) mung 30 peserta.

Kelompok CBL‑514 (n = 50) rata‑rata umur 46,3 taun, 94 % wanita, 86 % kulit putih, lan BMI rata‑rata 27,77. Kelompok plasebo mayoritas wanita (≈ 81 %). Mula, asil iki paling relevan kanggo wanita kanthi overweight moderat lan lemak abdomen.

Angka‑angka efektifitas (karo denominator)

Penulis nglaporaké manawa uji iki nepaki titik akhir utama lan kabeh titik akhir sekunder. Denominatoré nyusut ing follow‑up amarga kunjungan sing ilang, mula persentase kudu diwaca kanthi konteks.

Kehilangan ≥ 150 mL (ITT):

  • 4 minggu: CBL‑514 63,9 % (23/36; 95 % CI 46,22‑79,18) vs plasebo 17,4 % (4/23; 95 % CI 4,95‑38,78); P < 0,001.
  • 8 minggu: CBL‑514 69,6 % (16/23; 95 % CI 47,08‑86,79) vs plasebo 0 % (0/16); P < 0,001.

Kehilangan ≥ 200 mL (ITT):

  • 4 minggu: CBL‑514 58,3 % (21/36; 95 % CI 40,76‑74,49) vs plasebo 8,7 % (2/23; 95 % CI 1,07‑28,04); P < 0,001.
  • 8 minggu: CBL‑514 60,9 % (14/23; 95 % CI 38,54‑80,29) vs plasebo 0 % (0/16); P < 0,001.

Eksploratif ≥ 250 mL: 44,4 % (16/36) ing 4 minggu lan 52,2 % (12/23) ing 8 minggu mung ing grup CBL‑514. Ora ana peserta plasebo sing nggayuh angka iki.

Perubahan rata‑rata (ITT, least‑squares): beda antar‑kelompok ‑206,62 mL ing 4 minggu (95 % CI ‑276,09 nganti ‑137,16) lan ‑216,28 mL ing 8 minggu (95 % CI ‑288,28 nganti ‑144,28); loro‑loro P < 0,001.

Populasi PP (mung 30 peserta): beda antar‑kelompok ‑312,08 mL ing 4 minggu lan ‑276,83 mL ing 8 minggu. Subset iki dipilih kanthi ketat, mula asil katon luwih menguntungkan tinimbang ITT.

Perawatan sing dibutuhaké: saka 28 peserta CBL‑514 sing nggayuh ≥ 150 mL, 12 nindakake sawisé siji perawatan lan 10 sawisé loro. Iki berarti ≈ 79 % peserta entuk pengurangan sing signifikan sawise siji utawa loro perawatan. Penurunan paling gedhé sing kacathet yaiku luwih saka 750 mL ing siji peserta.

Bobot ora berubah (poin penting)

Bobot awak rata‑rata hampir ora owah. Kelompok CBL‑514 nuduhaké +0,45 kg ing follow‑up 4 minggu lan +0,02 kg ing 8 minggu, dibandhingake karo ‑0,76 kg lan ‑0,26 kg ing kelompok plasebo. Artikel nyatakake ana penurunan lemak lokal sanajan sawetara peserta malah nambah bobot luwih saka 1 kg (data detail ora ditampilaké). Iki nuduhaké yen volume lemak lokal bisa nyusut tanpa pangaruh signifikan marang bobot total awak—efek sing ora bisa diukur nganggo timbangan biasa.

Keamanan lan watesan utama

Pemantauan keamanan ngrekam adverse event sing muncul sawise perawatan, asil laboratorium, tanda vital, ECG, pemeriksaan fisik, lan reaksi ing situs suntikan. Papat peserta mundur amarga adverse event. Tulisan iki ora nampilaké rincian lengkap adverse‑event; kanggo informasi lengkap, waca bagean keamanan ing artikel asli.

Watesan utama:

  • Siji‑blind saja. Peneliti lan sponsor ngerti sapa sing nampa apa.
  • Keterlibatan sponsor ing desain, analisis, lan publikasi.
  • Attrisi dhuwur. Kira‑kira setengah peserta ora rampung, lan populasi per‑protocol mung 30.
  • Ukuran sampel eksploratif tanpa perhitungan power formal lan tanpa penyesuaian kanggo testing multivariat.
  • Follow‑up cekak: mung 8 minggu sawise perawatan pungkasan, saéngga durabilitas asil durung jelas.
  • Mayoritas wanita, mula generalisasi menyang pria cukup winates.
  • Perbandingan tidak langsung. Penulis mbandhingaké asil iki karo studi cryolipolysis lan nyebut asil CBL‑514 “sebanding karo sing digayuh karo liposuction”. Metode beda, lan ora ana uji head‑to‑head.
  • Kelonggaran kulit mung adhedhasar foto pasca‑perawatan, dudu titik akhir formal.
  • Status investigasi. Durung disetujoni, lan ora ana protokol suntikan mandiri kanggo konsumen.

Jelajahi rangkaian CBL‑514

Kesimpulan

Ing uji fase II iki, CBL‑514 nuduhaké penurunan lokal volume lemak abdomen sing jelas lan signifikan sacara statistik dibandhingake karo saline, nalika bobot awak tetep rata. Mekanisme aksi adhedhasar data non‑klinis perusahaan sing durung dipublikasikaké. Bukti sing kasedhiya isih cilik, didhukung sponsor, siji‑blind, lan follow‑up cekak kanthi attrisi dhuwur. Iki bisa dianggep minangka sinyal sing menjanjikan, nanging kudu dibuktekaké maneh kanthi uji luwih gedhé, suwé, lan double‑blind sadurunge bisa dianggep final.

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

Kepiye Cara Kerja CBL-514? Iki Ilmu Penjenengané

BY DR. SYNAPSE ·

CBL-514 ora dianggep minangka obat sing nglebur lemak. Klaimé ngganggu sinyal urip sel lemak lan nyurung sel kasebut mlebu proses apoptosis liwat DYRK1b, caspase‑3 lan Bax/Bcl‑2. Buktine asalé saka laporan perusahaan sing durung dipublikasikaké, dene struktur kimiane ora diwartakake. Uji fase 2 taun 2025 mung ngukur volume lemak nganggo ultrasonik lan foto, tanpa biopsi utawa data caspase. Artikel iki misahaké hipotesis molekuler saka apa sing saktenané diukur ing manungsa, kalebu tingkat dropout sing dhuwur lan rancangan single‑blind.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Apa CBL‑514 Tenan Ngobong Lemak? Kabeh Sing Kita Ngerti

BY HELIX WARD ·

Uji coba fase 2 CBL‑514 ing taun 2025 ora ngukur penurunan bobot awak, nanging nyoba apa suntikan langsung menyang jaringan lemak ing weteng bisa ngurangi paling ora 150 mL volume lemak subkutan sing diukur nganggo ultrasonik. Sawisé wolung minggu, 69,6 % (16 saka 23) partisipan sing nampa CBL‑514 nganti target iki, dene kelompok plasebo ora ana sing nggayuh. Nanging rata‑rata bobot awak malah ora mudhun (+0,02 kg), separo partisipan ora ngrampungake studi, lan jumlah partisipan sing netepi protokol mung 30 wong. Reaksi situs suntikan umum, kaya owah‑warna (71,4 %) lan rasa lara sing serius (18,4 %).

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

Dosis CBL‑514 – Apa sing Dikatakan Ilmu?

BY DR. SYNAPSE ·

Trial CBL‑514 iku protokol injeksi investigasional, lan angka “600 mg” iku wates maksimum saben perawatan, dudu dosis suplemen. Artikel iki nerangaké studi fase 2a sing nggolèki dosis (1,2, 1,6, lan 2,0 mg/cm² ing area 150 cm², n=43, open‑label) lan nerangaké asal‑usul angka 24,96 % sing asring disebut. Banjur dibahas fase 2 kanthi kontrol plasebo, sing tetep nganggo 2,0 mg/cm² nanging nambah area dadi 300 cm² lan wates dadi 600 mg. Sampeyan bakal ngerti kenapa total mg ora bisa dibandhingaké antarane studi, apa sing dilaporaké babagan keamanan, lan kenapa iki isih ora disetujui utawa dadi saran.

Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
research

Injeksi Penghilangan Lemak CBL-514: Apa Kata Ilmu?

BY DR. SYNAPSE ·

CBL-514 saiki wis liwat uji coba acak fase 2 sing dikontrol plasebo lan diterbitaké ing *Aesthetic Surgery Journal*. Penulis nglaporaké yèn uji iki nyukupi titik akhir utama lan sekunder, nanging desainé duwé akèh kekurangan: mung siji‑blind, sponsor melu ngrancang, nganalisa, lan nulis studi, lan tingkat drop‑out meh separo. Saka 75 peserta sing mlebu, mung 38 sing rampung, lan populasi sing diteliti mayoritas wanita lan kulit putih. Ing ngisor iki apa sing bisa didhukung uji iki, apa sing ora, lan kenapa iki dudu saran medis utawa bukti perawatan sing wis disetujui.

This page is available in